CRL Stock Recent News

Investors interested in stocks from the Medical Services sector have probably already heard of Icon PLC (ICLR) and Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?

Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible throug.

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.